The complex role of T-cell-based immunity in atherosclerosis

Current Atherosclerosis Reports

Volumn 10, Issue 3, 2008, Pages 236-243

  Aukrust, Pål ^a   Otterdal, Kari ^b   Yndestad, Arne ^b   Sandberg, Wiggo J ^b   Smith, Camilla ^b   Ueland, Thor ^b   Øie, Erik ^b   Damås, Jan K ^b   Gullestad, Lars ^b   Halvorsen, Bente ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CD28 ANTIGEN; CHEMOKINE; CYTOKINE; TUMOR NECROSIS FACTOR; INTERLEUKIN 17; TUMOR NECROSIS FACTOR ALPHA;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROTECTION; CELLULAR IMMUNITY; CHOLESTEROL DIET; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE CONTROL; DISEASE COURSE; DRUG RESEARCH; ENDOTHELIUM CELL; HELPER CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; LIPID OXIDATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; RISK FACTOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; VASCULAR ENDOTHELIUM; VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MACROPHAGE; METABOLISM; PHYSIOLOGY;

ATHEROSCLEROSIS; CYTOKINES; HUMANS; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; MACROPHAGES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49949117872     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0037-8     Document Type: Review

References (60)

1. Glass CK, Witztum JL: Atherosclerosis. The road ahead. Cell 2001, 104:503-516.
2. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med 2005, 352:1685-1695.
3. Robertson AK, Hansson GK: T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 2006, 26:2421-2432.
4. Zhou X, Nicoletti A, Elhage R, Hansson GK: Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000, 102:2919-2922.
5. Daugherty A, Rateri DL: T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation. Circ Res 2002, 90:1039-1040.
6. Harvey EJ, Ramji DP: Interferon-gamma and atherosclerosis: pro- or anti-atherogenic? Cardiovasc Res 2005, 67:11-20.
7. Liuzzo G, Kopecky SL, Frye RL, et al.: Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999, 100:2135-2139.
8. Ranjbaran H, Sokol SI, Gallo A, et al.: An inflammatory pathway of IFN-gamma production in coronary atherosclerosis. J Immunol 2007, 178:592-604.
9. Koga M, Kai H, Yasukawa H, et al.: Inhibition of progression and stabilization of plaques by postnatal interferon-gamma function blocking in ApoE-knockout mice. Circ Res 2007, 101:348-356.
10. Gupta S, Pablo AM, Jiang X, et al.: IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997, 99:2752-2761.
11. Whitman SC, Ravisankar P, Daugherty A: Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 2002, 90: E34-E38.
12. Liuzzo G, Vallejo AN, Kopecky SL, et al.: Molecular fingerprint of interferon-gamma signaling in unstable angina. Circulation 2001, 103:1509-1514.
13. Libby P, Sukhova G, Lee RT, Galls ZS: Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995, 25(Suppl 2):S9-S12.
14. Niwa T, Wada H, Ohashi H, et al.: Interferon-gamma produced by bone marrow-derived cells attenuates atherosclerotic lesion formation in LDLR-deficient mice. J Atheroscler Thromb 2004, 11:79-87.
15. Getz GS: Thematic review series: the immune system and atherogenesis. Immune function in atherogenesis. J Lipid Res 2005, 46:1-10.
16. Binder CJ, Hartvigsen K, Chang MK, et al.: IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004, 114:427-437.
17. Caligiuri G, Nicoletti A, Poirier B, Hansson GK: Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002, 109:745-753.
18. Freigang S, Horkko S, Miller E, et al.: Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998, 18:1972-1982.
19. Shimizu K, Shichiri M, Libby P, et al.: Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest 2004, 114:300-308.
20. Shimizu K, Libby P, Mitchell RN: Local cytokine environments drive aneurysm formation in allografted aortas. Trends Cardiovasc Med 2005, 15:142-148.
21. Davenport P, Tipping PG: The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003, 163:1117-1125.
22. Stockinger B, Veldhoen M, Martin B: Th17 T cells: Linking innate and adaptive immunity. Semin Immunol 2007, 19:353-361.
23. Bettelli E, Oukka M, Kuchroo VK: T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, 8:345-350.
24. Patel DN, King CA, Bailey SR, et al.: Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 2007, 282:27229-27238.
25. Venugopal SK, Devaraj S, Jialal I: Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005, 14:33-37.
26. Hashmi S, Zeng QT: Role of interleukin-17 and interlenkin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006, 17:699-706.
27. Halvorsen B, Waehre T, Scholz H, et al.: Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. J Lipid Res 2005, 46:211-219.
28. Waehre T, Halvorsen B, Damas JK, et al.: Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 2002, 32:803-810.
29. Tedgui A, Mallat Z: Interleukin-10: an anti-atherogenic cytokine? Eur J Clin Invest 2001, 31:1-2.
30. Grainger DJ: TGF-beta and atherosclerosis in man. Cardiovasc Res 2007, 74:213-222.
31. Robertson AK, Rudling M, Zhou X, et al.: Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 2003, 112:1342-1350.
32. Mor A, Planer D, Luboshits G, et al.: Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:893-900.
33. Ait-Oufella H, Salomon BL, Potteaux S, et al.: Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12:178-180.
34. de Boer OJ, van der Meet JJ, Teeling P, et al.: Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS ONE 2007, 2:e779.
35. Heller EA, Liu E, Tager AM, et al.: Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006, 113:2301-2312.
36. Wilczynski JR, Radwan M, Kalinka J: The characterization and role of regulatory T cells in immune reactions. Front Biosci 2008, 13:2266-2274.
37. Mausner-Fainberg K, Luboshits G, Mor A, et al.: The effect of HMG-CoA reductase inhibitors on naturally occurring CD4(+)CD25(+) T cells. Atherosclerosis 2007 [Epub ahead of print].
38. Oukka M: Interplay between pathogenic Th17 and regulatory T cells. Ann Rheum Dis 2007, 66(Suppl 3):iii87-iii90.
39. Mangan PR, Harrington LE, O'Quinn DB, et al.: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234.
40. Ludewig B, Freigang S, Jaggi M, et al.: Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci U S A 2000, 97:12752-12757.
41. Skjelland M, Michelsen AE, Krohg-Sorensen K, et al.: Plasma levels of granzyme B are increased in patients with lipid-rich carotid plaques as determined by echogenicity. Atherosclerosis 2007, 195:e142-e146.
42. Gotsman I, Grabie N, Dacosta R, et al.: Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest 2007, 117:2974-2982.
43. Olofsson PS, Söderström LÅ, Wagsater D, et al.: CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 2008, In press.
44. Wick G, Knoflach M, Xu Q: Autoimmune and inflammatory mechanisms in atherosclerosis. Ann Rev Immunol 2004, 22:361-403.
45. Damås JK, Waehre T, Yndestad A, et al.: Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation 2003, 107:2670-2676.
46. Houtkamp MA, van Der Wal AC, de Boer OJ, et al.: Interleukin-15 expression in atherosclerotic plaques: an alternative pathway for T-cell activation in atherosclerosis? Arterioscler Thromb Vasc Biol 2001, 21:1208-1213.
47. Buono C, Pang H, Uchida Y, et al.: B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2004, 109:2009-2015.
48. van Puijvelde GH, Hauer AD, de Vos P, et al.: Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006, 114:1968-1976.
49. Gotsman I, Grabie N, Gupta R, et al.: Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006, 114:2047-2055.
50. Sakaguchi S, Sakaguchi N, Asano M, et al.: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
51. Liuzzo G, Goronzy JJ, Yang H, et al.: Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000, 101:2883-2888.
52. Zhang X, Niessner A, Nakajima T, et al.: Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ Res 2006, 98:524-531.
53. Smook ML, Heeringa P, Damoiseaux JG, et al.: Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis 2005, 183:275-282.
54. Lee WH, Kim SH, Lee Y, et al.: Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol 2001, 21:2004-2010.
55. Otterdal K, Andreassen AK, Yndestad A, et al.: Raised LIGHT levels in pulmonary arterial hypertension - potential role in thrombus formation. Am J Respir Crit Care Med 2008, 177:202-207.
56. Otterdal K, Smith C, Oie E, et al.: Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. Blood 2006, 108:928-935.
57. Scholz H, Sandberg W, Damås JK, et al.: Enhanced plasma levels of LIGHT in unstable angina: possible pathogenic role in foam cell formation and thrombosis. Circulation 2005, 112:2121-2129.
58. van Wanrooij EJ, van Puijvelde GH, de Vos P, et al.: Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007, 27:204-210.
59. Damås JK, Boullier A, Waehre T, et al.: Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005, 25:2567-2572.
60. Schneider MA, Meingassner JG, Lipp M, et al.: CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells. J Exp Med 2007, 204:735-745.